- Fund Type: ETF
- Objective: Blend - Mid Cap
- Asset Class: Equity
- Geographic Focus: U.S.
Snapshot for Vanguard S&P Mid-Cap 400 ETF (0V1C)
| Open: | - | High - Low: | - | Primary Exchange: | Tradegate |
|---|---|---|---|---|---|
| Volume: | 0 | 52-Week Range: | - | Beta vs SPTRMDCP: | - |
Fund Profile & Information for 0V1C
Vanguard S&P Mid-Cap 400 ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the S&P Mid-Cap 400 Index.
| Inception Date: | Telephone: | 1-866-499-8473 | |
|---|---|---|---|
| Managers: | CHRISTINE D FRANQUIN | ||
| Web Site: | www.vanguard.com | ||
Fundamentals for 0V1C
| NAV | - |
|---|---|
| Assets (M) | (on 2013-04-30) 159.3509 |
| Shares out (M) | 0.00 |
| Market Cap (M) | 0.00 |
| % Premium | - |
| Average 52-Week % Premium | - |
| Fund Leveraged | N |
Dividends for 0V1C
| Dividend Type | Income |
|---|---|
| Dividend Frequency | Annual |
| Last Dividend Net | (on 2012-12-24) 0.7250 |
| Dividend Yield (ttm) | -% |
Performance for 0V1C
| 1-Month | - | 1-Year | - |
|---|---|---|---|
| 3-Month | - | 3-Year | - |
| Year To Date | - | 5-Year | - |
| Expense Ratio | 0.15 |
Top Fund Holdings for 0V1C
Filing Date: 03/31/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 15,515 | 2,736,893 | 1.003% |
| Kansas City Southern | 22,371 | 2,480,944 | 0.909% |
| Vertex Pharmaceuticals Inc | 44,312 | 2,435,831 | 0.892% |
| Equinix Inc | 9,912 | 2,144,065 | 0.785% |
| AMETEK Inc | 49,425 | 2,143,068 | 0.785% |
| HollyFrontier Corp | 41,339 | 2,126,892 | 0.779% |
| Church & Dwight Co Inc | 28,025 | 1,811,256 | 0.664% |
| Macerich Co/The | 27,897 | 1,796,009 | 0.658% |
| Realty Income Corp | 39,399 | 1,786,745 | 0.655% |
| Henry Schein Inc | 17,785 | 1,646,002 | 0.603% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page